NEW YORK--(BUSINESS WIRE)--April 20, 2006--Omrix Biopharmaceuticals, Inc. announced its initial public offering of 3,437,500 shares of common stock was priced at $10.00 per share. Shares of Omrix’s common stock will trade on the Nasdaq National Market under the symbol “OMRI”.
Omrix has granted the underwriters of this initial public offering a 30-day option to purchase up to an additional 515,625 shares of Omrix common stock at the public offering price to cover over-allotments, if any. UBS Investment Bank is acting as the sole book-running manager. CIBC World Markets is acting as co-lead manager and Leerink Swann & Company and Oppenheimer & Co. are co-managers.
A copy of the prospectus relating to the offering may be obtained by contacting UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, New York 10171 (212-821-3000).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Omrix Biopharmaceuticals, Inc.
Omrix is a commercial-stage biopharmaceutical company that develops and markets innovative biological products. Further information is available on the Internet at http://www.omrix.com.
Contact: Omrix Biopharmaceuticals, Inc. Michael Burshtine, 212-887-6500 mike.burshtine@omrix.com or Feinstein Kean Healthcare Courtney E. Harris, 617-671-6744 courtney.harris@fkhealth.com
Source: Omrix Biopharmaceuticals, Inc.
